scholarly journals High-flow nasal cannula oxygen therapy: more than a higher amount of oxygen delivery

2016 ◽  
Vol 8 (10) ◽  
pp. E1296-E1300
Author(s):  
Eric Maury ◽  
Mikael Alves ◽  
Naike Bigé
Keyword(s):  
Oxygen Delivery ◽  
Oxygen Therapy ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula

scholarly journals Is high flow nasal cannula as an effective oxygen delivery alternative in intensive care unit?

2019 ◽  
Vol 6 (2) ◽  
pp. 460
Author(s):  
Amrish Patel ◽  
Jitesh Atram ◽  
H. S. Dumra ◽  
Mansi Dandnaik ◽  
Gopal Raval
Keyword(s):  
Intensive Care ◽  
Respiratory Failure ◽  
Respiratory Rate ◽  
Oxygen Delivery ◽  
Oxygen Therapy ◽  
Work Of Breathing ◽  
High Flow ◽  
Nasal Cannula ◽  
Comfort Level ◽  
High Flow Nasal Cannula

Background: High-flow nasal cannula (HFNC) oxygen therapy is carried out using an air/oxygen blender, active humidifier, single heated tube, and nasal cannula. It is an oxygen delivery system which uses air blender to deliver accurate oxygen concentration to the patient from 21% to 100% at desired temperature. It can be administered via wide bore nasal cannula or to the tracheostomy tube via connector. It can give upto 60L/min flow hence can generate positive end expiratory pressure between 2 to 7 cmH20. By providing humidified oxygen along with the high flow rates it satisfies air hunger and reduces work of breathing for the patient.Methods: This is a retrospective observational study. Patients with persistent hypoxia in spite of conventional oxygen therapy were treated with HFNC. Patients with possible need for immediate invasive ventilator support were excluded. Clinical respiratory parameters and oxygenation were compared under conventional and HFNC oxygen therapy.Results: Thirty patients, aged more than 18 years admitted in intensive respiratory care unit with acute hypoxemic respiratory failure from June 2017 to January 2018 were included in the study. Study period was of 6 months. Etiology of acute respiratory failure (ARF) was mainly pneumonia (n = 17), interstitial lung disease (n = 5), bronchial asthma (n=3) and others (n = 5). There was statistically significant reduction in respiratory rate (29.40 before Vs 23.50 after; P- <0.0001) and significant improvement in comfort level of the patient after HFNC therapy. Median duration of HFNC was 48 hrs (24-360) hours. Five patients were intubated later on and 4 died in the intensive care unit.Conclusions: Use of HFNC in patients with persistent ARF was associated with significant and sustained improvement of clinical parameters (respiratory rate). It can be used comfortably for prolonged periods.

scholarly journals Effectiveness of High Flow Nasal Cannula and Standard Non-Rebreathing Mask for Oxygen Therapy in Moderate Category COVID-19 Pneumonia: A Randomized Controlled Study

2021 ◽  
Author(s):  
NAZIA Nazir ◽  
Anupriya Saxena ◽  
Hariom Solanki ◽  
Ruchi Pandey
Keyword(s):  
Patient Satisfaction ◽  
Oxygen Delivery ◽  
Oxygen Therapy ◽  
High Flow ◽  
Nasal Cannula ◽  
Satisfaction Level ◽  
High Flow Nasal Cannula ◽  
Delivery Device ◽  
Randomized Controlled ◽  
Initial Oxygen

Abstract Background: To compare the effectiveness of High Flow Nasal Cannula (HFNC) and standard non rebreathing mask (NRBM) as oxygen delivery device, in moderate cases of COVID-19 Pneumonia.Methods: A single-centre, prospective, open label randomized controlled trial was conducted between February 2021 and April 2021. Sixty enrolled patients were randomly divided into two groups according to the oxygen delivery device used. Group 1 (n = 30) received HFNC and group 2 (n = 30) received NRBM as initial oxygen delivery device, to maintain a target saturation of ≥ 96% in both groups. The success rate of oxygen therapy, time to progression to severe disease, PaO2, PaO2/FiO2 ratio, respiratory rate, heart rate, blood pressure, number of patients requiring NIV or endotracheal intubation, time for de-escalation of oxygen therapy to lower Fio2 device and patient satisfaction level were compared among the two groups.Results: Demographic, clinical variables and treatment given were comparable in the two groups. In the HFNC group 83.3% patients had successful outcomes with the initial oxygen therapy device used as compared to 66.6% in the NRBM group. However, the use of HFNC resulted in improved oxygenation (P < 0.001), better patient satisfaction (P < 0.001) and shorter time for de-escalation of oxygen therapy to a lower FIO2 device (3.75 ± 1.032 vs. 6.83 ± 0.928).Conclusions: HFNC is a reliable oxygen therapy modality for moderate category COVID-19 pneumonia that results in better oxygenation and a greater patient satisfaction level as compared to a non-rebreathing mask.Trial Registration: ctri.nic.in; Reg No: CTRI/2021/01/030829; Date of Reg: 05/02/2021

The starting rate for high‐flow nasal cannula oxygen therapy in infants with bronchiolitis: Is clinical judgment enough?

2021 ◽  
Author(s):  
Paola Papoff ◽  
Elena Caresta ◽  
Stefano Luciani ◽  
Alessandra Pierangeli ◽  
Carolina Scagnolari ◽  
...  
Keyword(s):  
Clinical Judgment ◽  
Oxygen Therapy ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula

High‐flow nasal cannula oxygen therapy for acute respiratory failure in a non‐intensive geriatric setting

2018 ◽  
Vol 18 (12) ◽  
pp. 1652-1653 ◽  
Author(s):  
Filippo Luca Fimognari ◽  
Massimo Rizzo ◽  
Olga Cuccurullo ◽  
Giovanna Cristiano ◽  
Roberto Ricchio ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Acute Respiratory Failure ◽  
Oxygen Therapy ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula
Sign in / Sign up

Export Citation Format

Share Document